US Housing Starts Decline to Lowest Level Since Early 2021

(Bloomberg) — New US home construction fell in July by more than forecast to the slowest pace since early last year as builders adjusted to a pullback in demand and a pickup in inventory.

Residential starts dropped 9.6% last month to a 1.45 million annualized rate from a revised 1.6 million pace in June, according to government data released Tuesday. The median forecast called for a 1.53 million pace.

Applications to build, a proxy for future construction, declined 1.3% to 1.67 million.

Starts of one-family homes were the weakest in more than two years, the report showed. After a pandemic-related housing boom forced builders to scramble to build enough homes to satisfy demand, high mortgage rates, elevated inflation and a deteriorating economic picture are now tempering sales. That’s left builders with a sizable number of unsold properties.

The outlook continues to deteriorate. A report Monday showed homebuilder sentiment slid for an eighth-straight month in August, marking the worst stretch since 2007.

While Home Depot Inc. on Wednesday reported better-than-expected second-quarter earnings, the home-improvement retailer also said that customer transactions continued to fall. Home Depot said transactions dropped 3% from a year ago.

Prices for commodities like lumber have eased in recent months, though builders continue to struggle to fill open positions, especially more skilled roles. Two-thirds of construction firms reported few or no qualified applicants in a July survey of small businesses.

The government’s report showed single-family housing starts decreased 10.1% to an annualized 916,000 rate, the slowest since June 2020. Permits for one-family dwellings dropped 4.3% to a two-year low. Meanwhile, construction of multifamily dwellings fell to 530,000 in July.

Existing-home sales for July will be released Thursday, followed by new-home purchase data next week.

Do you think inflation in the US has peaked? This week’s MLIV Pulse survey takes a hard look at prices. Please follow this link to share your views.

 

More stories like this are available on bloomberg.com.

©2022 Bloomberg L.P.

Follow us on social media for the latest updates in B2B!

Image

Latest

What the Future Looks Like if We Get It Right
What the Future Looks Like if We Get It Right
December 30, 2025

As the Patient Monitoring series concludes, the conversation shifts from today’s challenges to tomorrow’s possibilities. This final episode of the five-part Health and Life Sciences at the Edge series looks ahead to what healthcare could become if patient monitoring gets it right. Intel’s Kaeli Tully is joined by Sudha Yellapantula, Senior Researcher at Medical…

Read More
data center infrastructure
AI Is Forcing a Rethink of Data Center Infrastructure at Every Level
December 29, 2025

The data center industry is being redefined by AI’s demand for faster, denser, and more scalable infrastructure. According to McKinsey, average rack power densities have more than doubled in just two years. It went from approximately 8 kW to 17 kW, and is expected to hit 30 kW by 2027. Global data center power demand is projected…

Read More
Emergency department
How Predictive AI Is Helping Hospitals Anticipate Admissions and Optimize Emergency Department Throughput
December 24, 2025

Emergency departments across the U.S. are under unprecedented strain, with overcrowding, staffing shortages, and inpatient bed constraints converging into a throughput crisis. The American Hospital Association reports that hospital capacity and workforce growth have lagged, intensifying delays from arrival to disposition. At the same time, advances in artificial intelligence are moving from experimental to operational—raising…

Read More
Mission
Why Is the Mission of Benchmark So Important
December 23, 2025

As pharmaceutical innovation accelerates, the margin for error narrows, making quality assurance not just a regulatory necessity but a public good. Benchmark’s mission sits at the intersection of progress and protection—helping manufacturers stay aligned with FDA standards so life-saving therapies reach patients faster and safer. By keeping cleanrooms compliant and companies out of trouble, Benchmark…

Read More